We focus on FDA-approved GLP-1 care pathways.
Ro vs Hims
This is not a ranking. There is no score, and paid relationships never affect what's included or how it's described. Each fact below links to where we found it, in the provider's own words.
| Ro | Hims | |
|---|---|---|
| Category | Cash-pay telehealth | Cash-pay telehealth |
| Pricing | Membership costs $39 for the first month, then $74–$149 per month depending on the plan. The 12-month plan is $74/month prepaid annually, the 6-month plan is $89/month prepaid every six months, the 3-month plan is $99/month prepaid every three months, and the monthly plan is $149/month. Medication is billed separately from membership. | Membership starts at $39 for the first month, then $149/month. Branded medication is priced separately: $199/month for injectable Wegovy (pen), $149/month for oral Wegovy (pill), and $299/month for Zepbound (KwikPen or vial). |
| Medications listed | Offers Wegovy (pill and pen), Foundayo (pill), and Zepbound (KwikPen), with pricing tiers by dose. | In March 2026, Hims entered a partnership with Novo Nordisk (which concurrently dismissed its patent lawsuit against Hims) to expand access to FDA-approved GLP-1s, including Ozempic injections and Wegovy pills and injections. Hims no longer advertises compounded GLP-1s and is transitioning existing patients to FDA-approved options when clinically appropriate, though it states compounded semaglutide may still be offered on a limited basis if a provider determines it's clinically necessary. |
| Membership terms | The first month's $39 membership fee is refunded if a patient is found ineligible for GLP-1 treatment. Ro offers a free insurance coverage check for select medications and handles the related paperwork; membership is billed separately from medication and is a self-pay product. | Not published |
| BBB rating | B rating; BBB accredited since July 23, 2018. | Not Rated — BBB has insufficient information to issue a letter grade. |
| Trustpilot rating | 3.9 out of 5 ('Great'), based on 5,245 reviews. | Approximately 3.0 out of 5 based on roughly 8,000–9,000 reviews. |
| Years operating | Founded in 2017 (launched as 'Roman,' rebranded to 'Ro' in 2018). | Founded November 2017. |
| Company stage | Established — founded 2017, launched as 'Roman' (about 9 years). | Established — Hims launched in November 2017. |
| Verified | Aug 8, 2026 | Aug 2, 2026 |
Coverage and treatment decisions involve your health history. Talk with a licensed healthcare professional before starting or changing treatment.
Ro Body
Verified Aug 8, 2026·3 official sources
PillPen- Pricing
- Membership costs $39 for the first month, then $74–$149 per month depending on the plan. The 12-month plan is $74/month prepaid annually, the 6-month plan is $89/month prepaid every six months, the 3-month plan is $99/month prepaid every three months, and the monthly plan is $149/month. Medication is billed separately from membership.Source: ro.co
- Medications listed
- Offers Wegovy (pill and pen), Foundayo (pill), and Zepbound (KwikPen), with pricing tiers by dose.Source: ro.co
- Membership terms
- The first month's $39 membership fee is refunded if a patient is found ineligible for GLP-1 treatment. Ro offers a free insurance coverage check for select medications and handles the related paperwork; membership is billed separately from medication and is a self-pay product.Source: ro.co
- BBB rating
- B rating; BBB accredited since July 23, 2018.Source: bbb.org
- Trustpilot rating
- 3.9 out of 5 ('Great'), based on 5,245 reviews.Source: trustpilot.com
- Years operating
- Founded in 2017 (launched as 'Roman,' rebranded to 'Ro' in 2018).Source: bbb.org
- Company stage
- Established — founded 2017, launched as 'Roman' (about 9 years).Source: bbb.org
Hims Weight Loss
Verified Aug 2, 2026·5 official sources
PillPenInjection- Pricing
- Membership starts at $39 for the first month, then $149/month. Branded medication is priced separately: $199/month for injectable Wegovy (pen), $149/month for oral Wegovy (pill), and $299/month for Zepbound (KwikPen or vial).Source: hims.com
- Medications listed
- In March 2026, Hims entered a partnership with Novo Nordisk (which concurrently dismissed its patent lawsuit against Hims) to expand access to FDA-approved GLP-1s, including Ozempic injections and Wegovy pills and injections. Hims no longer advertises compounded GLP-1s and is transitioning existing patients to FDA-approved options when clinically appropriate, though it states compounded semaglutide may still be offered on a limited basis if a provider determines it's clinically necessary.Source: investors.hims.com
- BBB rating
- Not Rated — BBB has insufficient information to issue a letter grade.Source: bbb.org
- Trustpilot rating
- Approximately 3.0 out of 5 based on roughly 8,000–9,000 reviews.Source: trustpilot.com
- Years operating
- Founded November 2017.Source: hims.com
- Company stage
- Established — Hims launched in November 2017.Source: hims.com